The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)
DOI:
https://doi.org/10.2340/1651-226X.2024.34885Keywords:
targeted therapy, immunotherapy, whole genome sequencing, precision medicineAbstract
Background and purpose: The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted and immunotherapies outside their registered indication in patients with advanced or metastatic cancer.
Patients: Patients with advanced or metastatic cancer are eligible when there are no standard of care treatment options left and the tumor possesses a molecular genomic variant for which commercially available anticancer treatment is accessible off-label in DRUP. Clinical benefit is the study’s primary endpoint, characterized by a confirmed objective response or stable disease after at least 16 weeks of treatment.
Results: More than 2,500 patients have undergone evaluation, of which over 1,500 have started treatment in DRUP. The overall clinical benefit rate (CBR) remains 33%. The nivolumab cohort for patients with microsatellite instable metastatic tumors proved highly successful with a CBR of 63%, while palbociclib or ribociclib in patients with tumors harboring CDK4/6 pathway alterations showed limited efficacy, with a CBR of 15%. The formation of two European initiatives (PCM4EU and PRIME-ROSE) strives to accelerate implementation and enhance data collection to broaden equitable access to anticancer treatments and gather more evidence.
Conclusion: DRUP persists in improving patients access to off-label targeted or immunotherapy in the Netherlands and beyond. The expansion of DRUP-like clinical trials across Europe provides countless opportunities for broadening the horizon of precision oncology.
Downloads
References
Bins S, Cirkel GA, Gadellaa-Van Hooijdonk CG, et al. Implementation of a multicenter biobanking collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pretreatment tumor tissue diopsies. Oncologist. 2017;22(1):33–40.
https://doi.org/10.1634/theoncologist.2016-0085 DOI: https://doi.org/10.1634/theoncologist.2016-0085
About Hartwig Medical Foundation [Internet]. 2023. Available from: [Cited date: 22th of November 2023] https://www.hartwigmedicalfoundation.nl/over-ons/anbi/
Priestley P, Baber J, Lolkema MP, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575(7781): 210–16.
https://doi.org/10.1038/s41586-019-1689-y DOI: https://doi.org/10.1038/s41586-019-1689-y
van der Velden DL, Hoes LR, van der Wijngaart H, et al. The drug rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574(7776):127–31.
https://doi.org/10.1038/s41586-019-1600-x DOI: https://doi.org/10.1038/s41586-019-1600-x
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
https://doi.org/10.1016/j.ejca.2008.10.026 DOI: https://doi.org/10.1016/j.ejca.2008.10.026
Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: results From a nationally representative survey of oncologists in the United States. JCO Precis Oncol. 2018;2:PO.18.00169.
https://doi.org/10.1200/PO.18.00169 DOI: https://doi.org/10.1200/PO.18.00169
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
https://doi.org/10.1016/S1470-2045(14)70442-5 DOI: https://doi.org/10.1016/S1470-2045(14)70442-5
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.
https://doi.org/10.1200/JCO.2013.54.8800 DOI: https://doi.org/10.1200/JCO.2013.54.8800
Meric-Bernstam F, Johnson A, Holla V, et al. A decision support framework for genomically informed investigational cancer therapy. JNCI. 2015;107(7):djv098.
https://doi.org/10.1093/jnci/djv098 DOI: https://doi.org/10.1093/jnci/djv098
Roepman P, de Bruijn E, van Lieshout S, et al. Clinical validation of whole genome sequencing for cancer diagnostics. J Mol Diagn. 2021;23(7):816–33.
https://doi.org/10.1016/j.jmoldx.2021.04.011 DOI: https://doi.org/10.1016/j.jmoldx.2021.04.011
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10. DOI: https://doi.org/10.1016/0197-2456(89)90015-9
https://doi.org/10.1016/0197-2456 (89)90015-9
Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours. BMC Cancer. 2023;23(1):205.
https://doi.org/10.1186/s12885-023-10663-2 DOI: https://doi.org/10.1186/s12885-023-10663-2
van Berge Henegouwen JM, Jebbink M, Hoes LR, et al. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. Eur J Cancer. 2022;171:114–23.
https://doi.org/10.1016/j.ejca.2022.05.009 DOI: https://doi.org/10.1016/j.ejca.2022.05.009
Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, et al. Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res. 2022;28(7): 1402–11.
https://doi.org/10.1158/1078-0432.CCR-21-3752 DOI: https://doi.org/10.1158/1078-0432.CCR-21-3752
Geurts B, Zeverijn LJ, Battaglia TW, et al. Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: results of a tumor-agnostic DRUP cohort. J Clin Oncol. 2023;41(16_Suppl):2590.
https://doi.org/10.1200/JCO.2023.41.16_suppl.2590 DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.2590
van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann Oncol. 2019;30(5):663–5.
https://doi.org/10.1093/annonc/mdz119 DOI: https://doi.org/10.1093/annonc/mdz119
Diemer F. Farmacotherapeutisch rapport nivolumab (Opdivo®) bij de behandeling van dMMR/MSI solide tumoren na standaardbehandeling.: Zorginstituut, Diemen, Nederland; 2022.
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, et al. Patients with biallelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types. Clin Cancer Res. 2021;27(22):6106–14.
https://doi.org/10.1158/1078-0432.CCR-21-1104 DOI: https://doi.org/10.1158/1078-0432.CCR-21-1104
Verkerk K, van der Wel T, Zeverijn LJ, et al. 1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): results from the drug rediscovery protocol (DRUP). Ann Oncol. 2023;34:S797–8.
https://doi.org/10.1016/j.annonc.2023.09.2425 DOI: https://doi.org/10.1016/j.annonc.2023.09.2425
Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. Int J Cancer. 2023;153(7):1413–22. DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.3101
https://doi.org/10.1002/ijc.34649 DOI: https://doi.org/10.1002/ijc.34649
Dutch-Nordic Alliance for Precision Cancer Medicine launched [Internet]. 2021. Available from: [Cited date: 21th of November 2023] https://www.nki.nl/news-events/news/dutch-nordic-alliance-for-precision-cancer-medicine-launched/
Gelderblom H, Edsjö A, Russnes HEG, et al. 1711P The DRUP-like clinical trials family: a distributed European trial network for equitable access to precision medicine. Ann Oncol. 2023;34:S933–4.
https://doi.org/10.1016/j.annonc.2023.09.2665 DOI: https://doi.org/10.1016/j.annonc.2023.09.2665
Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023;22(3):213–34.
https://doi.org/10.1038/s41573-022-00615-z DOI: https://doi.org/10.1038/s41573-022-00615-z
Sachdeva A, Tiwari RC, Guha S. A novel approach to augment single-arm clinical studies with real-world data. J Biopharm Stat. 2022;32(1):141–57.
https://doi.org/10.1080/10543406.2021.2011902 DOI: https://doi.org/10.1080/10543406.2021.2011902
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Soemeya F. Haj Mohammad, Hans J.L. Timmer, Laurien J. Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Karlijn Verkerk, Florentine A.J. Verbeek, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
This work is licensed under a Creative Commons Attribution 4.0 International License.
Funding data
-
KWF Kankerbestrijding
Grant numbers 10014 -
HORIZON EUROPE Health
Grant numbers 101104269 -
European Commission
Grant numbers 101079984
